Semaglutide study in youth with autism spectrum disorder is recruiting in obesity and metabolic research
A ClinicalTrials.gov registry observation shows a phase 4 study of semaglutide in youth with autism spectrum disorder is recruiting, with BMI and skeletal muscle mass tracked over 12 months.
A phase 4 study of semaglutide in youth with autism spectrum disorder is recruiting, according to a ClinicalTrials.gov registry observation published 2026-11-09T00:00:00+00:00. For readers, the key point is simple: researchers are testing a drug commonly discussed in weight care alongside lifestyle counseling in a population with autism spectrum disorder, and the study is still open for enrollment.
The trial is titled Semaglutide in Youth With Autism Spectrum Disorder and is sponsored by Children's Hospital Medical Center, Cincinnati. It is listed as non-randomized, with one arm for Semaglutide + Autism Spectrum Disorder (ASD)-Tailored Lifestyle Management and a historical control for ASD-Tailored Lifestyle Management Alone.
What the study will measure
The main outcomes are set for 12 months. Researchers plan to track Number of Participants With Percent Change in BMI (kg/m2) from baseline to Month 12, along with Number of Participants With Change in Skeletal Muscle Mass (SMM).
That second measure matters because the registry also specifies body composition, not just weight. Skeletal muscle mass will be measured by bioimpedance anaysis (BIA), which is a way to estimate body composition using a small electrical current.
"Study outcomes require posted results." — ctgov_v2
How far along it is
The registry lists the overall_status as RECRUITING, with primary_completion_date estimated for 2028-09-01. That means the study is not finished, and there are no posted results in the record yet.
Because this is a registry observation, the practical value is in the design and status rather than any conclusion. The record gives a clear view of what the team plans to study, but not what the trial will ultimately show.
Why it sits inside a larger obesity and metabolic picture
This study appears in the live special event Obesity & Metabolic, alongside other registry observations that are also focused on obesity or weight-related care. Those include recruiting studies on sedation in obese patients, pharmacokinetics in adults with overweight or obesity, and a mobile app study for adolescents.
Taken together, the linked studies show a broad research field: medicines, procedures, behavior support, and measurement tools are all being tested in different groups. This semaglutide trial adds youth with autism spectrum disorder to that picture, while keeping the record's limits clear: it is a recruiting study, not a reported outcome.